title: [DGFIT: Immune and targeted therapy in urologic oncology – what can be expected?].
abstract: Immune and targeted therapy represent innovative therapy options in oncology. An overview of novel immune and targeted therapy options in urologic oncology presented at the most recent scientific urological and oncological meetings is given by representatives of the German Association of Immune and Targeted Therapy (DGFIT). Besides renal cell cancer, where targeted therapy is well established, new immune and targeted approaches in prostate and bladder cancer are discussed, summarizing current results and new developments with relevant impact for the treating physician.
authors.affiliation: Chirurgischen Klinik und Poliklinik Grosshadern, Klinikum der Universität München, Germany. hegele@med.uni-marburg.de
authors.forename: A
authors.initials: A
authors.lastname: Hegele
authors.forename: H
authors.initials: H
authors.lastname: Heinzer
authors.forename: D
authors.initials: D
authors.lastname: Rüttinger
authors.forename: M
authors.initials: M
authors.lastname: Siebels
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D019496:Cancer Vaccines / Q000008:administration & dosage* / Q000009:adverse effects; D002292:Carcinoma, Renal Cell / Q000556:secondary / Q000628:therapy; D002295:Carcinoma, Transitional Cell / Q000556:secondary / Q000628:therapy; D018450:Disease Progression; D004311:Double-Blind Method; D016503:Drug Delivery Systems / Q000009:adverse effects / Q000379:methods*; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000628:therapy; D008297:Male; D058990:Molecular Targeted Therapy / Q000379:methods*; D011471:Prostatic Neoplasms / Q000628:therapy; D016032:Randomized Controlled Trials as Topic; D001749:Urinary Bladder Neoplasms / Q000628:therapy; D014565:Urogenital Neoplasms / Q000628:therapy*
chemical_list: D000970:Antineoplastic Agents; D019496:Cancer Vaccines